There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Resmed (RMD – Research Report), Mineralys Therapeutics, Inc. (MLYS – Research Report) and Addus Homecare (ADUS – Research Report) with bullish sentiments.
Resmed (RMD)
In a report released today, Lyanne Harrison from Bank of America Securities maintained a Buy rating on Resmed, with a price target of $220.00. The company’s shares closed last Thursday at $193.73.
Harrison has an average return of
According to TipRanks.com, Harrison is ranked #7318 out of 8771 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $183.46 average price target.
See today’s best-performing stocks on TipRanks >>
Mineralys Therapeutics, Inc. (MLYS)
In a report released yesterday, Greg Harrison from Bank of America Securities reiterated a Buy rating on Mineralys Therapeutics, Inc., with a price target of $36.00. The company’s shares closed last Thursday at $13.09.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of
Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Moderate Buy with an average price target of $31.50, a 136.0% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $27.00 price target.
Addus Homecare (ADUS)
In a report released today, Joanna Gajuk from Bank of America Securities reiterated a Buy rating on Addus Homecare, with a price target of $115.00. The company’s shares closed last Thursday at $101.30.
According to TipRanks.com, Gajuk is a 3-star analyst with an average return of
Currently, the analyst consensus on Addus Homecare is a Strong Buy with an average price target of $105.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RMD:
- LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint
- ResMed’s 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Early notable gainers among liquid option names on March 7th
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed announces launch of AirFit F40
